Thomas Miller, MD
Allergy & Immunology · Grand Rapids, MINPI 1841210895
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 334 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 28.2% of the total. 2025 is the largest year on record at $1,424, 2.2 times the $645 reported in 2019.
Across 334 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$923
- GSK$912
- CSL Behring$457
- Genentech USA, Inc.$326
- Regeneron Healthcare Solutions, Inc.$305
- plus $2K from 17 others
What the payments were for
- Food & beverage$6,44998%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 99 | $1,858 |
| Sanofi | 33 | $923 |
| GSK | 68 | $912 |
| CSL Behring | 24 | $457 |
| Genentech USA, Inc. | 17 | $326 |
| Regeneron Healthcare Solutions, Inc. | 10 | $305 |
| Amgen | 15 | $275 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $245 |
| Novartis | 10 | $228 |
| Alk-abello, Inc | 11 | $224 |
| Phadia US Inc. | 2 | $211 |
| Teva Pharmaceuticals USA, Inc. | 6 | $100 |
| Lilly USA, LLC | 4 | $90 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $86 |
| Grifols USA, LLC | 3 | $75 |
| Pfizer | 3 | $46 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Optinose US, Inc. | 2 | $43 |
| Merck | 2 | $37 |
| Kaleo, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $28 |
| LEO Pharma Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,579 in reported general payments places this provider in the 70th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $45,285 |
| XolairOmalizumab | 13 | $36,946 |
| DuleraMometasone/Formoterol | 44 | $20,270 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 51 | $20,066 |
| Qvar RedihalerBeclomethasone Dipropionate | 26 | $18,198 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $14,289 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,877 |
| BreynaBudesonide/Formoterol Fumarate | 22 | $7,667 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $7,288 |
| Ipratropium Bromide | 96 | $6,373 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,015 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $3,571 |
| Epinephrine | 12 | $3,434 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $2,850 |
| Montelukast Sodium | 121 | $2,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $912 | $49,29956 claims |
| MerckDulera | $37 | $20,27044 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $100 | $18,19826 claims |
| Boehringer IngelheimSpiriva Respimat | $28 | $7,87712 claims |
| AstraZenecaSymbicort | $1,858 | $7,28819 claims |
| Hikma Pharmaceuticals USAEpinephrine | $13 | $3,43412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Grand Rapids
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Vincent DubravecGrand Rapids$4K
- Bradley BoelkinsGrand Rapids$3K
- Amanda HolsworthGrand Rapids$2K
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.